FDA Approval Alert: The Need-to-Know | Afamitresgene Autoleucel in Unresectable Synovial Sarcoma

In August 2024, the FDA granted accelerated approval to afamitresgene autoleucel as a treatment for adult patients with metastatic or unresectable synovial sarcoma previously treated with chemotherapy.

Brian A. Van Tine, MD, PhD, discusses potential evolutions in the treatment landscape following the FDA approval of afami-cel in metastatic synovial sarcoma.
Afami-cel Approval May Open Gateway for Synovial Sarcoma Advancements
Podcast
Aug 26, 2024 2:00 PM
Brian A. Van Tine, MD, PhD, discusses potential evolutions in the treatment landscape following the FDA approval of afami-cel in metastatic synovial sarcoma.
Accelerated approval of afami-cel may expand access to therapy for patients who are unable to live near certain treatment centers.
Afami-cel Approval in Sarcoma May Offer More Readily Accessible Therapy
Video
Aug 15, 2024 6:00 PM
Accelerated approval of afami-cel may expand access to therapy for patients who are unable to live near certain treatment centers.
Treatment with afami-cel may offer improved quality of life to patients with metastatic synovial sarcoma compared with continuous chemotherapy.
“Exciting” Response Durability Data Support Afami-cel Approval in Sarcoma
Video
Aug 14, 2024 8:00 PM
Treatment with afami-cel may offer improved quality of life to patients with metastatic synovial sarcoma compared with continuous chemotherapy.
FDA Clears HLA Typing Companion Diagnostic for Afami-cel in Sarcoma | Image Credit: © David A Litman - stock.adobe.com.
FDA Clears HLA Typing Companion Diagnostic for Afami-cel in Sarcoma
Article
Aug 7, 2024 4:00 PM
The SeCore CDx HLA A Sequencing System may help identify patients with advanced synovial sarcoma who are suitable to receive afami-cel.
Data from SPEARHEAD-1 support the accelerated approval of afamitresgene autoleucel in metastatic or unresectable synovial sarcoma.
Afami-cel Earns FDA Accelerated Approval in Unresectable Synovial Sarcoma
Article
Aug 2, 2024 12:58 PM
Data from SPEARHEAD-1 support the accelerated approval of afamitresgene autoleucel in metastatic or unresectable synovial sarcoma.